反式-2-[4-[(叔丁基氧羰基)氨基]环己基]乙醛 | 215790-29-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 反式-2-[4-[(叔丁基氧羰基)氨基]环己基]乙醛
• 中文别名: 反式-4-(BOC-氨基)环己烷乙醛
• 英文名称: 1,1-dimethylethyl[trans-4-(2-oxoethyl)cyclohexyl]carbamate
• 英文别名: trans-tert-butyl 4-(2-oxoethyl)cyclohexylcarbamate；trans-2-{1-[4-(N-tert-butoxycarbony)amino]cyclohexyl}acetaldehyde；trans-2-{1-[4-(N-tert-butoxycarbonyl)amino]cyclohexyl}acetaldehyde；tert-butyl trans-4-(2-oxoethyl)cyclohexylcarbamate；trans-2-(1-(4-(N-tert-butyloxycarbonyl)amino)cyclohexyl)acetaldehyde；[trans-4-(2-oxo-ethyl)cyclohexyl]carbamic acid tert-butyl ester；trans-{4-[(tert-butoxycarbonyl)amino]cyclohexyl}acetaldehyde；tert-butyl N-[4-(2-oxoethyl)cyclohexyl]carbamate
• CAS: 215790-29-7
• 化学式: C₁₃H₂₃NO₃
• 分子量: 241.331
• InChiKey: OPGBSEXLSWYFOR-UHFFFAOYSA-N

物化性质

• 沸点：
  360.6±11.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)
• 溶解度：
  微溶(0.41g/L)(25°C)。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
tert-Butyl trans-4-(2-oxoethyl)cyclohexylcarbamate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
tert-Butyl trans-4-(2-oxoethyl)cyclohexylcarbamate
Ingredient name:
CAS number: 215790-29-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H23NO3
Molecular weight: 241.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

反式-4-(BOC-氨基)环己烷乙醛是合成卡利哌嗪的中间体。卡利哌嗪是一种新型抗精神病药物，作用于多巴胺D3/D2受体。

反应信息

• 作为反应物：
  描述：

  反式-2-[4-[(叔丁基氧羰基)氨基]环己基]乙醛 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 trans-{4-[2-(4-benzo[1,3]dioxol-4-ylpiperazin-1-yl)ethyl]cyclohexyl}carbamic acid methyl ester
  参考文献：
  名称：

  NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS

  摘要：

  本发明涉及公式(I)的新型5-HT2A和D3受体的双重调节剂，其中n、Y、R1、R2、R3和R4如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及制备公式(I)化合物、含有它们的药物组合物以及它们作为药物代理的用途。

  公开号：

  US20130040948A1
• 作为产物：
  描述：

  4-N-BOC-环己基乙酸甲酯 在 二异丁基氢化铝 、 甲醇 作用下， 以 正己烷 、 甲苯 为溶剂， 生成 反式-2-[4-[(叔丁基氧羰基)氨基]环己基]乙醛
  参考文献：
  名称：

  Chromene compounds, a process for their preparationand pharmaceutical compositions containing them

  摘要：

  该发明涉及以下式（I）的化合物： 其中R1和R2共同形成以下含碳链： 其中： R3代表氢原子或烷基基团， R4代表氢原子或烷基、芳基、杂芳基、3,4-二氧代环丁烯基、烷基羰基、环烷基羰基、杂环烷基羰基、苯甲酰基、芳基磺酰基或杂芳基磺酰基基团，其中每个基团可选择地被取代， 或者R3和R4与携带它们的氮原子共同形成一个5-至8-成员环，因此形成的环可选择地被取代。 含有这些化合物的药物制剂在治疗需要D3受体拮抗剂的病症中很有用。

  公开号：

  US20110021490A1

文献信息

• BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090042943A1

  公开（公告）日：2009-02-12

  The present invention relates to compounds of formula (I) wherein R 1 and A are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D 3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT 2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及以下式（I）的化合物 其中R 1 和A如说明书中定义的作为血清素5-HT 2a 和多巴胺D 3 受体的双调节剂，它们的制备，含有它们的药物组合物以及它们作为药物的用途。一般式（I）的化合物对多巴胺D 3 和血清素（5-羟色胺；5-HT）5-HT 2A 受体具有高亲和力，并且在治疗精神分裂症等疾病以及抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍等其他疾病中具有有效性。
• [EN] ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSÉS D'ACYLAMINOCYCLOALKYLE APPROPRIÉS POUR LE TRAITEMENT DE TROUBLES RÉPONDANT À LA MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014064038A1

  公开（公告）日：2014-05-01

  The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula (I) as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula (I), the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2, R1 is hydrogen or C1-C3-alkyl, R2 is selected from the group consisting of hydrogen, and fluorine, R3a is selected from the group consisting of hydrogen and methyl, R3b is selected from the group consisting of hydrogen and methyl, R4 is branched C4-C6 alkyl or branched fluorinated C4-C6 alkyl, and R5 is an oxygen containing radical such as C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1-C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C5 cycloalkyl, fluorinated C3-C5 cycloalkyl, C3-C5 cycloalkoxy-C1-C4-alkyl and fluorinated C3-C5 cycloalkoxy-C1-C4-alkyl.

  本发明涉及新型酰胺环烷基化合物，特别是本文所述的具有以下式（I）的化合物及其盐和N-氧化物。这些化合物具有有价值的治疗性能，并且特别适用于治疗对多巴胺D3受体调节产生反应的疾病。在式（I）中，变量具有以下含义：m为1或2，n为1或2，A从CH2、CH2CH2、CHFCH2和CF2CH2组成的群体中选择，R1为氢或C1-C3-烷基，R2从氢和氟中选择，R3a从氢和甲基中选择，R3b从氢和甲基中选择，R4为支链C4-C6烷基或支链氟化C4-C6烷基，R5为含氧基团，例如C1-C2-烷氧基-C1-C4-烷基，氟化C1-C2-烷氧基-C1-C4-烷基，羟基-C1-C4-烷基，氟化羟基-C1-C4-烷基，氧杂环丙基，氟化氧杂环丙基，氧杂环戊基，氟化氧杂环戊基，C3-C5环烷基，氟化C3-C5环烷基，C3-C5环烷氧基-C1-C4-烷基和氟化C3-C5环烷氧基-C1-C4-烷基。
• [EN] M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR D'ACETYLCHOLINE MUSCARINIQUE M3
  申请人：GLAXO GROUP LTD

  公开号：WO2005094835A1

  公开（公告）日：2005-10-13

  Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

  提供了肌氨酸乙酰胆碱受体拮抗剂及其使用方法。
• D3 AND 5-HT2A RECEPTOR MODULATORS
  申请人：Gobbi Luca

  公开号：US20100075983A1

  公开（公告）日：2010-03-25

  The present invention provides compounds of the general formula (I) wherein X, n and R 1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

  本发明提供了一般式(I)的化合物，其中X、n和R1如本文所述，以及其药学上可接受的盐和酯，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物是血清素5-HT2a和多巴胺D3受体的双调节剂，在认知障碍、药物成瘾、抑郁症、焦虑症、药物依赖、痴呆症、记忆障碍、包括精神分裂症、情感性精神障碍、双相情感障碍、躁狂症、精神抑郁症以及偏执狂和妄想的精神病等的治疗和/或预防中有用。
• [EN] ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS<br/>[FR] COMPOSÉS PYRIDINIQUES ANNELÉS COMME MODULATEURS DUAUX DES RÉCEPTEURS 5-HT2A ET D3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011161009A1

  公开（公告）日：2011-12-29

  The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein X, Y, A, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

  本发明涉及公式（I）中的新型5-HT2A和D3受体的双调节剂，其中X、Y、A、R1、R2和R3如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及制备公式（I）化合物，包括它们的药物组合物以及它们作为药物的用途。